Dimensional Fund Advisors
APLS

Dimensional Fund Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Dimensional Fund Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,338,995
Closed -$53.7M – 3230
2026
Q1 		$53.7M Buy
1,338,995
+1,158,070
+640% +$25M 0.01% 1460
2025
Q4 		$4.54M Buy
180,925
+162,235
+868% +$3.81M ﹤0.01% 2554
2025
Q3 		$423K Buy
+18,690
New +$436K ﹤0.01% 3020
2024
Q3 		– Sell
-33,696
Closed -$1.29M – 3354
2024
Q2 		$1.29M Sell
33,696
-34,448
-51% -$1.56M ﹤0.01% 2867
2024
Q1 		$4.01M Buy
68,144
+32,577
+92% +$2.08M ﹤0.01% 2602
2023
Q4 		$2.13M Buy
35,567
+9,500
+36% +$482K ﹤0.01% 2779
2023
Q3 		$992K Sell
26,067
-105,720
-80% -$4.64M ﹤0.01% 2930
2023
Q2 		$12M Buy
131,787
+37,801
+40% +$3.26M ﹤0.01% 2171
2023
Q1 		$6.2M Buy
+93,986
New +$5.42M ﹤0.01% 2413
2022
Q3 		$5.64M Buy
+82,594
New +$4.89M ﹤0.01% 2385
2022
Q1 		– Sell
-9,828
Closed -$465K – 3510
2021
Q4 		$465K Sell
9,828
-574
-6% -$22.6K ﹤0.01% 3182
2021
Q3 		$343K Buy
+10,402
New +$584K ﹤0.01% 3251

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Dimensional Fund Advisors's APLS Position: Q2 2026 in Review

Dimensional Fund Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,338,995 shares — an estimated $53.7M sold.

Dimensional Fund Advisors first reported a position in APLS in Q3 2021 and held it in 12 quarters. The position peaked at $53.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Dimensional Fund Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Dimensional Fund Advisors sold 1,338,995 Apellis Pharmaceuticals shares in Q2 2026, an estimated $53.7M.
  • Dimensional Fund Advisors first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 12 quarters.
  • Dimensional Fund Advisors's Apellis Pharmaceuticals position peaked at $53.7M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.